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Abstract 
Extracellular vesicles (EVs) are small reservoirs of different molecules and important mediators of cell-to-cell communica- 
tion. As putative vehicles of misfolded protein propagation between cells, they have drawn substantial attention in the field 
of amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Moreover, exosome-mediated non-coding 
RNA delivery may play a crucial role in ALS, given the relevance of RNA homeostasis in disease pathogenesis. Since EVs 
can enter the systemic circulation and are easily detectable in patients’ biological fluids, they have generated broad interest 
both as diagnostic and prognostic biomarkers and as valuable tools in understanding disease pathogenesis. Here, after a brief 
introduction on biogenesis and functions of EVs, we aim to investigate their role in neurodegenerative disorders, especially 
ALS. Specifically, we focus on the main findings supporting EV-mediated protein and RNA transmission in ALS in vitro 
and in vivo models. Then, we provide an overview of clinical applications of EVs, summarizing the most relevant studies 
able to detect EVs in blood and cerebrospinal fluid (CSF) of ALS patients, underlying their potential use in aiding diagnosis 
and prognosis. Finally, we explore the therapeutic applications of EVs in ALS, either as targets or as vehicles of proteins, 
nucleic acids and molecular drugs. 
 
Keywords Extracellular vesicles · Amyotrophic lateral sclerosis · Prion-like properties · Biomarkers · Neurodegenerative 
disorders · Therapeutics 
 
Abbreviations 
ALS Amyotrophic Lateral sclerosis 
ASCs Adipose stem cells 
BBB Blood brain barrier 
C9-ALS C9orf72-related ALS 
C9orf72 Chromosome 9 open reading frame 72 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CTF C-terminal fragment 
DPRs Dipeptide repeat proteins 
EVs Extracellular vesicles 
FTD Frontotemporal dementia 
FTLD Frontotemporal lobar degeneration 
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FUS Fused-in-sarcoma 
HRE Hexanucleotide repeat expansion 
IL-6 Interleukin-6 
iPSC Induced pluripotent stem cell 
lnRNAs Long non-coding RNAs 
miRNAs Micro-RNAs 
MN Motor neuron 
mRNAs Messenger RNAs 
MVBs Multivesicular bodies 
MVs Microvesicles 
NIR Novel INHAT repressor 
PrLD Prion-like domain 
pTDP-43 Phosphorylated-TDP-43 
RBP RNA-binding protein 
ROS Reactive oxygen species 
sALS Sporadic ALS 
SOD1 Superoxide dismutase 
TDP-43 TAR DNA-binding protein 43 
 
 
 
Introduction 
 
Extracellular vesicles (EVs) are cell-derived reservoirs 
of diff ent molecules, proteins and factors, providing a 
crucial mean of communication and material exchange 
between adjoining and distant cells. They have recently 
gained a wide relevance in the fi d of amyotrophic lateral 
sclerosis (ALS), and neurodegenerative disorders overall, 
both as carriers of misfolded pathological proteins and 
non-coding regulatory RNAs and as vehicles of interplay 
between neurons and glial cells within central nervous sys- 
tem (CNS). Moreover, since detectable in patients’ biolog- 
ical fl  EVs have become attractive clinical tools with 
wide applications in diagnosis, prognosis and therapeutics. 
 
 
 
Extracellular vesicles: biology and functions 
 
EVs are encapsulated particles enriched in several mol- 
ecules, including membrane and cytoplasmic proteins, 
lipids and nucleic acids. As shuttles, they deliver molecu- 
lar cargoes to recipient cells within a biological system, 
representing one of the most relevant mechanisms of inter- 
cellular communication both in physiological and patho- 
logical processes. 
EVs may be classifi according to size, biogenesis 
and biochemical composition and are subdivided into 
microvesicles (MVs) and exosomes [1]. MVs range from 
approximately 100–150 to 1000 nm in diameter and are 
shed by budding of plasma membrane. Unlike exosomes, 
their production is mainly calcium-dependent; other fac- 
tors like cellular stress and immune response may trigger 
MV release. Conversely, exosomes have diameters between 
30 and 150 nm, sometimes overlapping with MVs, and are 
generated by inward budding of endosomal multivesicu- 
lar bodies (MVBs) [2]. Depending on the cargo they are 
delivering, MVBs can either fuse with lysosome entering 
the protein degradation pathway or be transported to the 
plasma membrane and released by exocytosis. Exosomes 
are then exported into the extracellular space and are able 
to enter the body circulation and to cross the blood brain 
barrier (BBB) [3]. Further, they are detectable in biofl  
like cerebrospinal fluid (CSF), blood and urine [4, 5], so 
they have acquired great relevance in the study of neuro- 
logical disorders. 
Surrounded by a phospholipid bilayer, EVs protect 
molecules from degradation and enable their delivery to 
adjacent and distant recipient cells. Donor cell type and 
physiological state determine the cargo and the composi- 
tion of EVs and defi their primary function. First, EVs 
can carry biologically active mediators involved in many 
biological processes, aimed to maintain homeostasis [6]. 
For instance, morphogens act stimulating development and 
cellular growth and diff entiation [7], molecules released 
by tumor cell-derived EVs provoke angiogenesis, prolif- 
eration and metastasis [8], and bioactive lipids promote 
cytokine secretion, which in turn may induce chemotaxis, 
infl or apoptosis. Additionally, they might func- 
tion as vehicles for elimination of unnecessary materials, 
playing a neuroprotective role. Similarly, exosomes have 
been shown to deliver active enzymes to assist degrada- 
tion of potential toxic proteins [9]. Further, other than 
transporting useful proteins, EVs enable genetic mate- 
rial exchange between cells. Indeed, messenger RNAs 
(mRNAs) can be send to the recipient cells, where they 
are translated into functional proteins; besides, micro- 
RNAs (miRNAs) and long non-coding RNAs (lnRNAs) 
delivered by EVs may regulate gene expression in recipi- 
ent cells [10]. 
All cell types in the CNS can release EVs, including neu- 
rons, astrocytes, oligodendrocytes and microglia [11]. In vitro 
studies [12, 13] have reported the high contribution of neu- 
ronal EVs, particularly exosomes, into synaptic activity modu- 
lation, since they can regulate the neurotransmitter release and 
the amount of post-synaptic receptors, as well as the neuronal 
excitability. MVs released by microglia are mainly involved 
in cytokine secretion, other than enhancing excitatory trans- 
mission [14], while microglial exosomes likely play a role 
in immunity [15]. Conversely, exosomes released by oligo- 
dendroglia are involved in neuronal firing rate and survival, 
since they can induce the transcription of genes implicated in 
stress response [16]. Astrocytes release a variety of EVs and 
according to their cargoes may mediate neurogenesis and syn- 
aptogenesis, myelination and neuroprotection or immunoregu- 
latory and anti-apoptotic effects [17]. Importantly, astrocyte- 
derived MVs contain glutamate transporters and provide to 
their subcellular localization [18], consistently with astrocyte 
function of scavengers of extracellular glutamate. 
Interestingly, a longitudinal study aimed at evaluating age- 
related physiological changes in plasma EVs has shown a 
decrease in EV concentration due to higher B-cell-mediated 
internalization and variation in protein composition with age 
[19]. Specifically, reduced levels of apoptotic markers (e.g. 
p-53, caspase-3) and enrichment in proteins involved in tumo- 
rigenesis and metastasis have been found in older patients, sug- 
gesting that EV characterization may provide relevant insights 
into paraphysiological processes like aging and potentially on 
age-related chronic diseases. 
 
 
 
 
Extracellular vesicles in neurodegenerative 
disorders 
 
Neurodegenerative disorders have been increasingly rec- 
ognized as proteinopathies, namely diseases resulting 
from abnormal deposition of misfolded and/or aggregated 
proteins. A growing body of evidence has pointed at a 
prion-like propagation as a possible mechanism underly- 
ing cell-to-cell protein transmission [20, 21]. According 
to this prion-like hypothesis, misfolded proteins can be 
transferred to healthy cells, induce their endogenous coun- 
terpart to misfold and lead to the amplifi of these 
pathological seeds, prompting the onset and the progres- 
sion of neurodegenerative disorders [22]. The spreading 
of the seeds between anatomically connected brain areas 
may occur through endocytosis/pinocytosis [23], tunneling 
nanotubes [24] and EV-mediated secretion [25]. 
A number of proteins, including Aβ, α-synuclein and 
tau have been found to colocalize with exosomes [26–31], 
supporting the role of EVs as potential drivers of patho- 
logical protein transmission and consequent neurodegen- 
eration. Conversely, exosomes delivering proteolytical 
enzymes active against extracellular Aβ would suggest 
their biological role in preventing neurodegeneration [9]. 
Moreover, there is also counteractive evidence suggesting 
that pathological proteins can be transmitted as free pro- 
teins and seed propagation may occur through mechanisms 
other than exosome-based secretion [32]. 
In addition, the concept of neurodegenerative disor- 
ders as “non-cell autonomous” diseases is progressively 
gaining round, thus, in this context EV-mediated cell–cell 
communication, as well as neuronal–glial interplay, may 
play a crucial role in disease pathogenesis [33]. Neuroin- 
fl has been suggested as putative mechanism in 
neurodegenerative disorders. In this context, given their 
ability to produce immunomodulatory cytokines, glial 
cells, and especially microglia, are able to sense neuronal 
activity and to infl synaptic transmission in response 
to infl ory stimuli. 
Indeed, microglia-derived EVs generated in infl    - 
tory conditions harbor different cargoes (pro-inflammatory 
cytokines and miR-155) compared to EVs derived from 
homeostatic microglia [34]. Other than inducing detri- 
mental eff     on neurons, the production of infl      - 
tory mediators and reactive oxygen species (ROS) leads 
to further microglial activation, generating a vicious cycle 
of infl and neurodegeneration. In a recent study 
[35], MVs from inflammatory microglia were enriched in a 
set of miRNAs involved in regulation of key synaptic pro- 
tein expression. Prolonged exposure to miR-146a-5p-con- 
taining EVs, which inhibits the expression of presynaptic 
synaptotagmin1 and postsynaptic neuroligin1, induced 
signifi   dendritic spine loss and decrease in density 
and strength of excitatory synapses. Consistently, astro- 
cyte-derived exosomes from AD patients display higher 
expression of TNFα, IL-1β and IL-6 and higher level 
of complement proteins respect to controls [36]. In PD, 
microglial-derived EVs release several pro-infl ory 
molecules in response to oxidative stress, causing harmful 
eff       on dopaminergic neurons [37]. 
Notably, neuroprotective eff of glial cell-derived 
EVs in neurodegenerative disorders have been described 
as well, as shown by secretion of anti-inflammatory 
astrocyte-derived factors in parkinsonian brains [37]. In 
addition, exosomes isolated by adipose stem cells (ASCs) 
display neuroprotective and anti-apoptotic eff on an 
in vitro model of ALS [38]. Taken together, these fi 
support a dual role for EV-mediated glial-neuron crosstalk 
in neurodegenerative disorders. 
Therefore EVs, particularly exosomes, have generated 
signifi  interest in the fi   of neurodegenerative disor- 
ders, given their application both in understanding disease 
pathogenesis and in improving diagnosis, prognosis and 
therapeutics of neurologic disorders. 
ALS is a devastating disorder due to degeneration of 
upper and lower motor neurons (MNs). The pathological 
hallmark underlying most of ALS cases and half of the 
cases of frontotemporal lobar degeneration (FTLD) is the 
deposition of nuclear and cytoplasmic inclusions of TAR 
DNA-binding protein 43 (TDP-43) and phosphorylated- 
TDP-43 (pTDP-43) [39]. ALS-affected patients experi- 
enced focal weakness and atrophy, with subsequent clini- 
cal involvement of neighboring districts. The spreading 
of symptomatology to contiguous regions seems to trace 
clinically the transmission of misfolded proteins occurring 
on a molecular level between adjoining cells and within 
interconnected CNS areas. 
Here, we aim to investigate the main functions of EVs 
in ALS, highlighting their role in disease pathogenesis. 
In particular, we summarize in vitro and in vivo evidence 
of EV-mediated prion-like misfolded protein propagation 
in ALS, focusing on the proteins encoded by the main 
ALS-causative genes, i.e. superoxide dismutase 1 (SOD1), 
TARDBP, Fused-in-sarcoma (FUS) and Chromosome 9 
open reading frame 72 (C9orf72). Then, since alteration of 
RNA homeostasis is a crucial process in ALS, we provide 
an overview on EV-mediated non-coding RNA transmis- 
sion and we point out the contribution of miRNAs into the 
regulation of gene expression in ALS. Finally, we explore 
the various applications of EVs in the fi  of motor neu- 
ron disorders and we underline their relevance as tools 
for pathogenesis comprehension, biomarkers in disease 
diagnosis and prognosis, as well as potential vehicles or 
targets for therapeutic approaches. 
 
 
 
Evidence of prion‑like EV‑mediated 
misfolded protein propagation 
in amyotrophic lateral sclerosis 
 
Several proteins encoded by genes causative of ALS and 
involved in disease pathogenesis have been characterized 
over the past decades. Recent evidence suggests that many 
of these proteins have been retrieved in EVs and travel 
between neuronal and glial cells and within diff ent brain 
areas, contributing to disease spreading and propagation 
[40]. Among them, particular mention has to be done to 
SOD1, TDP-43, FUS and dipeptide-repeat proteins (DPRs) 
(Table 1). 
SOD1 is a cytosolic and mitochondrial enzyme involved 
in clearance of superoxide molecules. Misfolded SOD1 
aggregates have been reported in spinal MNs and glial 
cells of familial ALS (fALS) cases harboring SOD1 
mutations and of some sporadic forms (sALS) [41, 42]. 
Interestingly, SOD1 has been the first ALS-associated pro- 
tein retrieved in EVs. In particular, SOD1 has been found 
in association with exosomes derived from mouse motor 
neuron-like NSC-34 cells overexpressing wild-type and 
mutated SOD1 [43]. The authors speculate about the pos- 
sible protective role of SOD1-positive exosomes against 
the physiological production of ROS outside the plasma 
membrane. A few years later, SOD1 overexpressing astro- 
cytes have been shown to release mutant SOD1-containing 
exosomes able to prompt MN death [44], thus suggesting 
that astrocytes and EVs may contribute to neuronal toxic- 
ity and disease spreading. After that, seed conversion of 
wild-type SOD1 by its misfolded counterpart has been 
demonstrated in intracellular compartments [45, 46], Grad 
and colleagues have provided evidence that misfolded 
native and mutated SOD1 can be transmitted from cell to 
cell through exosome-dependent and independent fashion 
 
 
Table 1  Proteins with relevance for ALS identified in extracellular vesicles from in vitro and in vivo models and ALS patients 
Protein Study   Extracellular vesicles   Sample/model Main finding 
In vitro and in vivo studies 
SOD1 [43] Exosomes Mouse MN-like NSC-34 cells Possible protective role of SOD1-containing 
exosomes against ROS 
SOD1 [44] Exosomes SOD1 overexpressing astrocytes Astrocyte-derived exosomes contribute to neu- 
ronal toxicity 
 
SOD1 [47] Exosomes Mouse MN-like NSC-34 cells SOD1 is transmitted from cell to cell through 
    exosomes and misfolding native SOD1 is 
 
SOD1 
 
[48] 
 
Exosomes 
 
Rat microglial cells 
efficiently perpetuated in naïve cells 
Microglial cells release SOD1-containing 
exosomes and are toxic to neurons 
SOD1 [49] Exosomes and MVs SOD1 transgenic mouse SOD1 is secreted in vivo in EVs derived from 
astrocytes and neurons 
TDP-43 [50] Exosomes Human neuroblastoma cells Phosphorylated TDP-43 aggregates can propa- 
gate from cell-to-cell via exosomes 
TDP-43 [53] Exosomes U251 cells TDP-43-containing exosomes from CSF from 
ALS/FTD patients has prion-like transmissible 
properties in vitro 
 
TDP-43 [55] Exosomes and MVs HEK-293 cells and primary mouse neurons Intracellular transmission and seeding properties 
TDP-43 [56] Exosomes Neuro2a cells and TDP-43 transgenic mouse Cytoplasmic TDP-43 localization in vitro; 
possible contribution in TDP-43 neuronal 
clearance in vivo 
FUS [58] Exosomes SH-SY5Y and N2A cells FUS secretion in FUS-overexpressing cells 
DPRs [61] Exosomes iPSC-derived MNs from C9orf72-related ALS 
patients 
Cell-to-cell DPR transmission 
Human studies 
SOD1, 
TDP-43 
and FUS 
 
[82] MVs Plasma of sALS patients Elevated levels in ALS compared to controls 
TDP-43 [54] Exosomes CSF of ALS patients CSF brain-derived exosomes contain TDP-43, 
reflecting neuropathology 
 
 
ALS amyotrophic lateral sclerosis, CSF cerebrospinal fluid, DPRs dipeptide-repeat proteins, EVs extracellular vesicles, FTD frontotemporal 
dementia, FUS fused-in-sarcoma, iPSC induced pluripotent stem cell, MN motor neuron, MVs microvesicles, ROS reactive oxygen species, sALS 
sporadic ALS, SOD1 superoxide dismutase, TDP-43 TAR DNA-binding protein 43 
 
 
 
 
and that propagated misfolding of native SOD1 may be 
effi y perpetuated into naïve cells [47]. Further, cell 
exposure to conditioned media derived from SOD1 overex- 
pressing HEK293 cells induces intracellular accumulation 
of misfolded SOD1, while this does not occur after condi- 
tioned media depletion from EVs [47]. SOD1 overexpress- 
ing microglial cells have been found to release SOD1-con- 
taining exosomes as well [48]. Besides, they have shown 
toxicity in co-culture with primary neurons, which can be 
alleviated by treatment with the autophagy-inducer treha- 
lose [48]. These fi strongly support the role of EVs 
in misfolded protein propagation following a prion-like 
fashion. Recently, a study performed in SOD1 transgenic 
mouse model has shown that misfolded SOD1 protein is 
enriched in EVs released by neurons and astrocytes [49]. 
TARDBP encodes for mainly nuclear RNA-binding 
protein (RBP) involved in splicing and RNA metabolism. 
Aggregates of phosphorylated and ubiquitinated TDP-43 
are the main neuropathological findings in brains from 
ALS patients [39]. C-terminal fragment (CTF) of TDP-43 
contains a prion-like domain (PrLD) which allows pro- 
tein–protein interaction and is able to induce seed-dependent 
aggregation in vitro [50]. Most of TARDBP disease-causing 
mutations involve CTF [51] and induce TDP-43 cytoplasmic 
mislocalization and pathological aggregate formation [52], 
resulting in RBP aberrant sequestration and impairment of 
RNA metabolism and proteostasis. 
Exposure of TDP-43-expressing human neuroblastoma 
cells to insoluble TDP-43 from brains of ALS and fron- 
totemporal dementia (FTD) patients results in template 
aggregation; moreover, pTDP-43 aggregates can be propa- 
gated from cell to cell at least partly via exosomes [50]. 
TDP-43 enrichment in EV fraction of CSF from ALS/FTD 
patients [53, 54] also supports the role of EVs in disease 
propagation. Moreover, CSF enriched in TDP-43-contain- 
ing exosomes may act as seed in vitro, since it is able to 
prompt accumulation of toxic TDP-43 CTF in cell lysates 
[53]. Further and definitive evidence of exosome-mediated 
secretion and prion-like propagation of TDP-43 aggregates 
has emerged from the study of Feiler and colleagues [55]. 
Indeed, exosomes and MVs containing TDP-43 oligomers 
have shown intercellularly transmission, as well as seeding 
properties [55]. Finally, Iguchi and colleagues demonstrated 
that exosomal TDP-43 secretion is upregulated in brains 
from ALS patients and may induce cytoplasmic redistribu- 
tion of TDP-43 in Neuro2a cells [56]. However, inhibition 
of exosome secretion in vivo increases TDP-43 aggregation 
and exacerbates the phenotype of TDP-43 transgenic mice, 
suggesting that exosomes may also be implied in neuronal 
clearance of TDP-43 [56]. 
Mutations in FUS are responsible of a subset of cases 
of familial and sporadic ALS. Similarly to TDP-43, FUS 
encodes for a RBP and its mutations may prompt protein 
cytoplasmic mislocalization with subsequent sequestra- 
tion of RNA transcripts and stress granules-like structure 
formation [57]. FUS immunoreactive inclusions have been 
found in neuronal and glial cells of patients affected by FUS- 
related fALS [57], suggesting that FUS abnormal deposition 
may exert neuronal toxicity and death, similarly to TDP-43 
and SOD1. Recent evidence has proven that FUS colocalize 
with exosomes derived from wild-type and mutated FUS- 
expressing cells [58], possibly indicating that EVs might 
participate in cell-to-cell FUS propagation. 
Hexanucleotide repeat expansion (HRE) in C9orf72 are 
the most common genetic cause of both fALS and sALS. 
Along with inclusions of phosphorylated and ubiquitinated 
TDP-43, post-mortem tissues from patients with C9orf72- 
related ALS (C9-ALS) have shown the presence of DPRs 
derived from non-canonical translation of sense and anti- 
sense HRE-containing transcripts [59]. DPR-mediated 
toxicity is crucial for C9-ALS pathogenesis and is consid- 
ered one of the major drivers of neuronal death [60]. DPR 
intercellular transmission via exosome-dependent and inde- 
pendent pathways has been demonstrated in spinal MNs 
from C9-ALS patients and DPRs transfected NSC-34 cells 
[61]. Although causality with neuronal death has not been 
reported, DPRs have been found to propagate from neurons 
to glial cells and viceversa, likely accounting for pathology 
propagation in C9-ALS [61]. 
Taken together, these findings advocate the crucial con- 
tribution of EVs into the spreading of toxic proteins across 
CNS, and consequently in neurodegeneration (Fig. 1). 
 
 
 
Non‑coding RNAs and EVs in ALS 
 
As mentioned earlier, nucleic acids are one of the principal 
cargoes retrieved in EVs, in addition to proteins. The phos- 
pholipid bilayer surrounding EVs guarantees RNA stability 
in extracellular space and in biofluids, preventing degrada- 
tion by ribonucleases. Other than mRNAs, transmission of 
non-coding RNAs provides regulation of gene expression by 
promoting or inhibiting translation in recipient cells, thereby 
providing us with valuable insight into cell functioning and 
disease pathogenesis. 
This is particularly relevant in ALS, given that alteration 
in RNA homeostasis is a well-recognized pathomechanism. 
Indeed, some ALS-causing genes (e.g. TARDBP and FUS) 
are involved in RNA processing and activity and some miR- 
NAs may alter the expression of proteins involved in ALS. 
Moreover, the depletion of Dicer, an enzyme crucial for 
miRNA biogenesis, leads to MN death [62]. Accordingly, 
non-coding RNAs and especially miRNAs have become 
promising tools useful to better understand disease patho- 
genesis [63, 64]. 
 
 
 
 
 
Fig. 1 Extracellular vesicle cell transmission and their clinical appli- 
cations in amyotrophic lateral sclerosis. Extracellular vesicles (EVs) 
mediate cell-to-cell transmission of misfolded proteins (e.g. SOD1, 
TDP-43 and FUS) in the central nervous system (CNS). EVs can 
be detectable in blood and cerebrospinal fluid (CSF) of amyotrophic 
lateral sclerosis (ALS) affected patients, providing diagnostic and 
prognostic biomarkers. After their purification from patients’ bio- 
fluids, EVs may be manipulated to accommodate proteins, non-cod- 
ing RNAs or drugs, and subsequently transferred back to the same 
patients, serving as therapeutic vehicles 
 
A few studies have successfully elucidated the role of 
miRNAs carried by EVs in modulating ALS phenotype and 
pathogenesis. 
After previous evidence of exosome-mediated SOD1 
cell-to-cell transmission as mechanism of disease spreading, 
Pinto and colleagues have shown that wild-type and mutated 
SOD1 transfected NSC-34 MNs are able to transfer miRNA- 
enriched exosomes to N9 microglial cells, thus influencing 
their inflammatory properties [65]. Indeed, increased expres- 
sion of miR-124 has been found in SOD1-mutated MNs 
and in their derived exosomes and reduction of microglial 
phagocytic activity, persistent Nf-KB activation, as well as 
upregulation of genes involved in inflammation in microglia 
has been observed [65]. Moreover, miR-124 has been previ- 
ously correlated to astrocyte diff entiation through Sox2 
and Sox9 targeting [66] and to the modulation of EAAT-2 
expression in astrocytes [67], which is consistent with the 
role of glutamate excitotoxicity in ALS pathogenesis. Given 
the putative role of inflammation in ALS pathogenesis, these 
works may provide new hints into the therapeutic modula- 
tion of microglia activation and astrocyte functioning using 
miRNA-containing exosomes. 
Given the involvement of astrocytes in the pathogenesis 
of SOD1-related ALS, miRNA profile in exosomes released 
by SOD1-mutated astrocytes has been investigated, despite 
no significant difference has been found compared to wild- 
type SOD1 cells [68]. Conversely, EVs released by astro- 
cytes derived from ALS patients carrying C9orf72 HRE 
present decreased levels of miR-494-3p, a negative regulator 
of proteins involved in axonal maintenance [69]. Restoration 
of miR-494-3p levels increases survival in MNs, suggest- 
ing that this miRNA may represent a promising therapeutic 
target [69]. 
Additionally, recent researches have investigated the 
utility of circulating miRNAs in EVs derived from ALS 
patients’ blood as potential biomarkers. 
MiR-27a-3p, a miRNA involved in myoblast–osteoblast 
interaction, was detected at decreased concentrations in 
exosomes derived from ALS serum in comparison to healthy 
controls [70]. To obtain an ALS-associated miRNA signa- 
ture, Saucier and colleagues have used a next-generation 
sequencing approach on EVs extracted from plasma of 
patients with ALS respect to healthy controls [71]. Differ- 
ential expression of 22 miRNAs has been observed between 
ALS and controls and deregulation of miRNAs with rel- 
evance for ALS (i.e. miR-9-5p, miR-183-5p, miR-338-3p, 
miR-1246) has been identifi [71]. Interestingly, miR- 
15a-5p and miR-193a-5p have been linked to ALS diagnosis 
 
 
 
 
and progression, respectively [71]. Similarly, neuronal- 
derived EVs extracted from plasma of ALS patients have 
shown deregulation of 30 miRNAs compared to healthy con- 
trols [72]. Deregulated miRNAs were involved in synaptic 
vesicle-related pathways and among these, 4 miRNAs have 
been similarly deregulated in motor cortex samples of ALS 
patients [72]. Using an analogous approach, a recent work 
identified a potential miRNA fingerprint in neural-enriched 
EVs: 5 miRNAs (miR-146a-5p; miR-199a-3p; miR-151a-3p; 
miR-151a-5p; miR-199a-5p) showed an up-regulation in 
ALS samples, while 3 miRNAs (miR-4454; miR-10b-5p; 
miR-29b-3p) were found to be downregulated in ALS com- 
pared to healthy controls [73]. Of note, dysregulation of 
miR-199a-3p and miR-4454 was identified also by Saucier 
et al. [71] and miR-199a-3p was associated to cell growth, 
axonal regeneration and plasticity. Moreover, miR-146a-5p, 
a miRNA involved in synaptic plasticity and inflammatory 
response, showed reduced expression in CSF of patients 
with ALS [74] and seems to play a relevant role in Spinal 
Muscular Atrophy (SMA) as well [75]. As previously men- 
tioned, miR-146a-5p-containing EVs are able to reduce den- 
dritic spine density and miniature synaptic currents in rats, 
due to inhibition of synaptotagmin1 and neuroligin1 [35]. 
MiR-151a-5p, which is linked to cell viability and oxidative 
stress response, has shown increased expression in blood 
and CSF samples from patients with AD [76] and PD [77]. 
Finally, it is worth mentioning that blood levels of miR- 
151a-5p, miR199a-5p, miR199a-3p, identifi as upregu- 
lated in ALS by Banack and colleagues, have shown a sig- 
nificant correlation with clinical parameters [78]. 
Although still at infancy, these studies have opened the 
path for the utilization of EVs as elegant and innovative 
tools to study non-coding RNAs, possibly informative in 
ALS pathogenesis and diagnosis. Since the main function 
of miRNAs is to downregulate mRNA expression through 
translation block or transcript degradation, it is reasonable 
that recently identified miRNAs will add piece of informa- 
tion about disease-related genes and pathways. So far, only 
one study has successfully performed a RNA sequencing of 
mRNAs from CSF exosomes in ALS patients, identifying 
several candidate genes playing a role in processes related 
to ALS pathogenesis, such as unfolded protein response, 
ubiquitin–proteasome system and oxidative stress [79]. 
 
 
Clinical application of EVs in ALS 
 
EVs as biomarkers of diagnosis and prognosis 
 
Despite several research efforts in elucidating disease 
mechanisms, ALS pathogenesis is still not completely 
understood. Moreover, a number of experimental therapeu- 
tic approaches have been tested so far, without successful 
results. Non-invasive measurable and reliable biomarkers 
are urgently needed to achieve earlier patient diagnosis and 
inclusion in clinical trial, prognostic estimation and drug 
monitoring [80]. 
CNS-derived exosomes have been demonstrated to cross 
the BBB and enter the systemic circulation, being easily 
detectable in biological fl ids like blood, CSF and urine. 
They carry specific molecular signatures, reflecting the cell 
status and functioning during disease condition, thus pro- 
viding precious information about disease pathogenesis. 
Moreover, they can be easily isolated from patients’ blood 
and CSF through a minimally invasive maneuver [81], serv- 
ing as sources of potential biomarkers in neurodegenerative 
disorders, including ALS. 
A few studies have investigated the feasibility of this 
approach in biofluids from patients with ALS (Table 1). A 
recent work aimed to characterize number, size and content 
of EVs retrieved from plasma has found increased mean 
size in ALS patients compared to healthy controls, but no 
numerical difference between the two groups [82]. MVs but 
not exosomes of ALS patients were enriched in ALS-related 
proteins, including SOD1, TDP-43, pTDP-43 and FUS, con- 
fi ming the fi of in vitro studies in support of EV- 
mediated prion-like propagation of ALS disease [82]. Simi- 
larly, TDP-43 has been retrieved in brain-derived exosomes 
from CSF of ALS patients, possibly reflecting in vivo the 
underlying neuropathological findings [54]. Moreover, 
leukocyte-derived MVs have been found at elevated levels 
in ALS patients and have shown a slight correlation with 
progression rate at the last visit, possibly representing bio- 
markers of disease progression [83]. 
Besides, analyses of patients’ biofl have drawn the 
attention on new proteins possibly involved in ALS patho- 
genesis. Consistent with the role of infl in ALS, 
Chen and colleagues have found elevated levels of interleu- 
kin-6 (IL-6) in astrocyte-derived exosomes retrieved from 
plasma of sALS patients, in addition to a positive correlation 
between their levels and rate of disease progression [84]. 
A proteomic study performed on exosome-enriched frac- 
tion of CSF has revealed increased concentration of novel 
INHAT repressor (NIR), involved in nucleolar function, in 
ALS patients [85]; interestingly NIR has shown altered sub- 
cellular localization in MNs of affected patients. 
 
EVs as therapeutic tools 
 
Other than helpful promising biomarkers, exosomes, and 
EVs overall, can be employed as potential therapeutics, 
either as targets or as vehicles of molecules relevant for cell 
functioning and crosstalk. 
EVs are putative carriers of pathological misfolded 
proteins in neurodegenerative diseases; thereby, attenuat- 
ing their functions might be benefi      to hamper the seed 
 
 
 
transmission and to prevent the development of neurodegen- 
eration. In this context, several approaches targeting different 
stages of vesicles’ pathways could be exploited, including 
vesicle formation, release, trafficking and uptake [86]. These 
strategies have been already applied in infl and 
cancer, but their application in the field of neurodegenerative 
disorders should be taken into account. 
The use of EVs as efficient systems to deliver molecules 
(e.g. proteins, genetic material or drugs) targeting cells or 
tissues likely represents the most innovative field of applica- 
tion. There are several advantages of using EVs as carriers 
of relevant biological molecules. First, they are highly stable 
in circulating system, in a way that can reach also distant 
targets; moreover, exosomes can cross the BBB [3] ena- 
bling the transport of cargoes to the CNS, being particularly 
appealing for the treatment of neurologic disorders. Then, 
compared to liposome- and nano-based therapies, they have 
cell-surface molecules and high affinity for tissues, reducing 
the risk of off  arget eff  as well as avoiding phagocy- 
tosis or degradation by macrophages. In addition to their 
excellent biocompatibility and poor immunogenicity and 
toxicity, EVs show high availability, since they can easily 
be retrieved from patients’ biofluids. Ideally, after isolating 
exosomes from cell cultures or patients’ blood, they can be 
manipulated to accommodate proteins, non-coding RNAs 
or drugs, and subsequently transferred back to the same 
patients (Fig. 1). 
It is worth mentioning that stem cells secrete exosomes 
containing cell-derived factors, which, through a paracrine 
eff can modulate the surrounding biological environ- 
ment. Mesenchymal stem cells (MSCs) can be easily iso- 
lated from adult and fetal tissues, including adipose tissue, 
and their several beneficial effects (tissue homeostasis, repair 
and regeneration) are at least partially mediated by exosome 
secretion [6]. Exosomes derived from human mesenchymal 
stem cells selectively promoted neurite outgrowth in corti- 
cal neuron cultures [87]. This strategy has been considered 
extremely attractive and valuable in the treatment of neuro- 
degenerative disorders, including ALS. 
At this purpose, exosomes isolated from murine ASCs 
have been shown to protect wild-type and SOD1-mutated 
MN-like NSC-34 cells from oxidative stress, increas- 
ing cell viability [88]. Similarly, they had the ability 
of restoring complex I activity, coupling effi and 
mitochondrial membrane potential [89]. Proteomic analy- 
sis performed on ASC-derived exosomes confi med their 
putative neuroprotective role, revealing the expression of 
proteins involved in cell adhesion and negative regula- 
tion of apoptosis [38]. Moreover, ASC-derived exosomes 
were effective in reducing aggregation of SOD1 and 
modulating mitochondrial dysfunction in neuronal cells 
from SOD1 mouse models [90]. In parallel, the use of 
ASCs and their exosomes as therapeutic tools in ALS has 
been validated in vivo as well. Systemic administration of 
ASCs in SOD1-mutated mouse delayed motor deteriora- 
tion, increased MN number and neurotrophin levels into 
murine spinal cord [91]. A recent study demonstrated 
that repeated administrations of ASC-derived exosomes 
improved motor performance in SOD1-mutated mouse, 
protected spinal MNs from neurodegeneration, preserved 
neuromuscular junction, muscle morphology and function- 
ing, and reduced glial cell activation [92]. Additionally, 
intranasally delivered exosomes were able to reach brains 
of wild-type mice and to home to injured brain regions of 
SOD1-mutated counterparts. 
However, there are also some limitations hampering the 
translation of EVs in clinical therapies, which are mainly 
related to the challenge of purifying the scarce number of 
exosomes from the human body and of determining the best 
source for their retrieval. In addition, the optimization of 
vesicle loading and dosage is equally important to maintain 
the structure and the content of exosomal membranes with- 
out altering functional efficacy. Finally, the problem of how 
to reach selectively the target cells must be addressed. 
 
 
 
Concluding remarks 
 
The development and the spreading of ALS and other neu- 
rodegenerative disorders have been linked to the cell-to-cell 
propagation of misfolded proteins in a prion-like fashion. 
Although a wide body of evidence supporting the role of 
EVs in this process in ALS, in vivo studies are still poor. 
Further, there is also contrasting evidence pointing at a bene- 
ficial role of EVs in disease pathogenesis. Nonetheless, EVs 
have undoubtedly added a piece of knowledge in understand- 
ing disease pathomechanisms. Moreover, the isolation of 
peripheral and brain-derived EVs from patients’ biofl 
have provided valuable insights into their clinical applica- 
tion as diagnostic and prognostic biomarkers, enabling the 
study in vivo of molecular and pathological correlates of 
ALS. Despite not being so close to their use as therapeu- 
tics in the oncoming futures, the findings fulfilled so far are 
promising and should encourage further research efforts in 
this direction. 
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